Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Novo Nordisk has filed a lawsuit against Singaporean biotech company KBP Biosciences, alleging fraud in relation to a hypertension and kidney disease drug deal. Novo seeks $830 million in damages, claiming they were misled by the biotech's founder. In other news, Biogen and Stoke have teamed up to develop a treatment for Dravet syndrome, with potential payments of up to $385 million to Stoke. Additionally, Arcus challenges Merck in kidney cancer treatment, Cour Pharmaceuticals enters the myasthenia gravis arena after 10 years of work. On the financial side, AlgoTx faced setbacks in a non-opioid pain trial, while Moderna reported higher-than-expected losses. On a different note, RFK Jr. signals support for the psychedelics space. Lastly, the FDA faces challenges as the Trump administration seeks to dismantle the workforce, leading to concerns about job security within the agency. Thank you for tuning in to Pharma and Biotech Daily.